Associations - IDH2 mutation

IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	enasidenib Sensitive: A1 - Approval
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + azacitidine Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	BGB-290 Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Leukemia Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Myelodysplastic Syndrome MDS	enasidenib Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Glioma Glioma	AG-881 Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Glioma Glioma	TG02 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + enasidenib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + RO5503781 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	CFI-400945 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Glioblastoma GBM	temozolomide gel Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Sarcoma Sarcoma	olaparib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	7+3 (DAC) Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine + clofarabine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine + cladribine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	decitabine + clofarabine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	decitabine + cladribine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	SEL24 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Glioblastoma GBM	M7824 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	azacitidine + enasidenib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	bosutinib Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	ponatinib Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	APO866 Sensitive: D – Preclinical